Telegram-Icon YouTube-Icon whatsapp-Icon

Q-Line Biotech IPO is an SME IPO with Fresh issue only and Book Built Issue. The company will raise upto 214 crore 48 lakh 47 thousand Six hundred rupees for 62,53,200 shares from the IPO. The IPO issue size is 62,53,200 shares (aggregating up to 214 crore 48 lakh 47 thousand Six hundred rupees), fresh issue: 62,53,200 shares (aggregating up to 214 crore 48 lakh 47 thousand Six hundred rupees) and offer for sale: NIL. is the lead manager and Purva Sharegistry (India) Pvt Ltd is the registrar of IPO. The IPO will open for subscription on 21 May 2026 and close on 25 May 2026. The basis of allotment will be decided on 26 May 2026 and Q-Line Biotech IPO shares will be listed on 29 May 2026 at NSE SME. Price band for IPO is ₹326 to ₹343 per share, minimum and maximum amount required for retail investor is ₹2,74,400 (800 shares, 2 lots), minimum amount required for sHni investor is ₹4,11,600 (1,200 shares, 3 lots) and maximum amount for which shni investor can apply for is ₹9,60,400 (2,800 shares, 7 lots). Minimum amount required for bHni investor is ₹10,97,600 (3,200 shares, 8 lots).

Q-Line Biotech IPO Details, Price, Market Lot

Q-Line Biotech IPO Details
IPO Open Date
IPO Close Date
IPO Issue Size
Issue (Sale Type)
Fresh Issue
Offer for Sale
Offered to Public
Reserved for Market Maker
Market Maker
Share Holding (Pre Issue)
Share Holding (Post Issue)
Listing At
Q-Line Biotech IPO Price
has set a price band of , lot size is of and face value is .
Face Value
Price Band
₹326 to ₹343 per share
Lot Size
400 shares
IPO Issue Type
Q-Line Biotech IPO Time Table
IPO will open for subscription on and close on . Basis of Allotment will be decided on , initiation of refund will begin on and IPO will be listed on at .
IPO Open Date
IPO Close Date
Basis of Allotment Date
Initiation of Refunds
Credit of Share to Demat Account
IPO Listing Date
IPO Cut-off time (UPI mandate confirmation)
Q-Line Biotech IPO Reservation
Total shares offered by IPO is . Out of which is reserved for retail, is reserved for HNI (NII), is reserved for QIB, and is reserved for market maker .
Retail Quota
NII Quota
QIB Quota
Market Maker Quota
Total
Company Promotor & Promotor's Holding
Pre Issue Promotor Holding
Post Issue Promotor Holding
Q-Line Biotech IPO Registrar
Q-Line Biotech IPO Lead Manager
is the book running lead manager, is the registrar and the market maker of the IPO
IPO Financial Indicator (valuations)
Market Capitalization
Debt/Equity
ROE
ROCE
RONW
P/BV
PAT Margin
EBITDA
Q-Line Biotech IPO P/E ratio and EPS
EPS (Pre IPO)
EPS (Post IPO)
P/E ratio (Pre IPO)
P/E ratio (Post IPO)

Q-Line Biotech IPO Lot Size and Required Amount

has set a price band of and lot size is of . Retail investors can bid for a minimum and maximum of lots ( shares), requiring an investment of . Small HNI (sHNI) investors can bid for a minimum of lots ( shares), requiring an investment of and maximum of lots ( shares), requiring an investment of . Big HNI (bids > 10 Lakh, bHNI) investors can bid for a minimum of Lots ( shares), requiring an investment of . Calculated at the cut-off price (the upper end of the price band).

Number of Shares Per Lot =
Application Lot(s) Shares Amount
Retail (Minimum)
Retail (Maximum)
S-HNI (Minimum)
S-HNI (Maximum)
B-HNI (Minimum)
Number of Shares Per Lot =
Application Lot(s) Shares Amount
Retail (Min)
Retail (Max)
S-HNI (Min)
S-HNI (Max)
B-HNI (Min)
Q-Line BiotechFinancials (Restated Consolidated)
Annual Performance (31 Mar 25 vs 31 Mar 24)
Q-Line BiotechFinancials (Restated Consolidated)'s Assets increased by 34.3%, Revenue increased by 56.3%, Profit After Tax dropped by 18.3%, EBITDA increased by 89.5%, Net Worth increased by 17.4%, Total Borrowing increased by 2.9%, Reserves & Surplus increased by 94.4% compared to the previous financial year.
Assets
▲ 34.3% (116.24)
Revenue
▲ 56.3% (116.13)
Profit After Tax
▼ 18.3% (-6.31)
EBITDA
▲ 89.5% (33.69)
Net Worth
▲ 17.4% (28.14)
Total Borrowing
▲ 2.9% (4.71)
Reserves & Surplus
▲ 94.4% (91.46)

Previous Financial Year Growth (31 Mar 24 vs 31 Mar 23)
Comparing 31 Mar 24 with 31 Mar 23, Assets increased by 34.8%, Revenue increased by 11.7%, Profit After Tax increased by 7.3%, EBITDA increased by 14.1%, Net Worth increased by 27%, Total Borrowing increased by 27.4%, Reserves & Surplus increased by 31.6%.
Assets (Prev Yr)
▲ 34.8% (87.67)
Revenue (Prev Yr)
▲ 11.7% (21.64)
Profit After Tax (Prev Yr)
▲ 7.3% (2.34)
EBITDA (Prev Yr)
▲ 14.1% (4.65)
Net Worth (Prev Yr)
▲ 27% (34.44)
Total Borrowing (Prev Yr)
▲ 27.4% (34.45)
Reserves & Surplus (Prev Yr)
▲ 31.6% (23.26)

2-Year Performance Change (31 Mar 23 To 31 Mar 25)
Between 31 Mar 25 and 31 Mar 23, Assets increased by 81.1%, Revenue increased by 74.5%, Profit After Tax dropped by 12.4%, EBITDA increased by 116.3%, Net Worth increased by 49.1%, Total Borrowing increased by 31.1%, Reserves & Surplus increased by 155.8%.
Assets (2-Yr Change)
▲ 81.1% (203.91)
Revenue (2-Yr Change)
▲ 74.5% (137.77)
Profit After Tax (2-Yr Change)
▼ 12.4% (-3.97)
EBITDA (2-Yr Change)
▲ 116.3% (38.34)
Net Worth (2-Yr Change)
▲ 49.1% (62.58)
Total Borrowing (2-Yr Change)
▲ 31.1% (39.16)
Reserves & Surplus (2-Yr Change)
▲ 155.8% (114.72)
  31 Dec 25 In Cr. 31 Mar 25 In Cr. 31 Mar 24 In Cr. 31 Mar 23 In Cr.
Assets 561.34 455.49 339.25 251.58
Revenue 236.5 322.58 206.45 184.81
Profit After Tax 38.69 28.13 34.44 32.1
EBITDA 64.23 71.32 37.63 32.98
Net Worth 229.16 189.95 161.81 127.37
Total Borrowing 243.85 164.95 160.24 125.79
Reserves & Surplus 212.89 188.37 96.91 73.65
Contact & Address
Address:
Phone:
Email:
Website:
IPO Prospectus

Q-Line Biotech IPO Object of Issue

S.No
Objects
Amount (in ₹, Cr)
1
To meet Working Capital requirements
93.50
2
Repayment of certain borrowing availed by the Company, in part or full
90.00
3
General Corporate Purposes
Total:
183.50

Q-Line Biotech IPO FAQs

Q-Line Biotech IPO is an SME IPO. The company will raise upto 214 crore 48 lakh 47 thousand Six hundred rupees for 62,53,200 shares. Face value is ₹10 per share, Price band is ₹326 to ₹343 per share, and cutt off price is ₹343 per share. The IPO opens on 21 May 2026 and closes on 25 May 2026. Purva Sharegistry (India) Pvt Ltd is the registrar and shares of Q-Line Biotech IPO will be listed at NSE SME.

The issue size of IPO is 62,53,200 shares (aggregating up to 214 crore 48 lakh 47 thousand Six hundred rupees). For fresh issue: 62,53,200 shares (aggregating up to 214 crore 48 lakh 47 thousand Six hundred rupees) and for offer for sale: NIL.

Price band for IPO is ₹326 to ₹343 per share.

The lot size of Q-Line Biotech IPO is of . Minimum order quantity for retail investor is 800 shares (2 lots) and required amount is ₹2,74,400. Minimum order quantity for sHNI is 1,200 shares ( lots) and required amount is ₹4,11,600. Minimum order quantity for bHNI investor is 3,200 shares ( lots) and required amount is ₹10,97,600.

The investors portion reserved for QIB is 29,69,200 shares (47.48%), reserved for HNI is 8,91,600 shares (14.26%) and 20,79,200 shares (33.25%) reserved for retail investors.

The IPO will be available for subscription from 21 May 2026 to 25 May 2026. IPO open date is 21 May 2026 and close date is 25 May 2026.

Allotment date for IPO is 26 May 2026. On the allotment date, after the IPO allotment status is announced, investors can check their IPO application allotment status on their respective IPO registrar.

The registrar for IPO is Purva Sharegistry (India) Pvt Ltd.

The IPO will be listed on 29 May 2026 at NSE SME.